Boundless Bio, Inc. (BOLD)

9.05 -0.95 (-9.50%) At close: 04:00PM EDT

Boundless Bio, Inc.

9880 Campus Point Drive
Suite 120
San Diego, CA 92121
United States
(858) 766-9912
https://boundlessbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 72

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jonathan E. Lim M.D.	Co-Founder & Independent Chairman	N/A	N/A	1972
Mr. Zachary Hornby	CEO, President & Director	721.05k	N/A	1979
Dr. Christian Hassig Ph.D.	Chief Scientific Officer	563.55k	N/A	1973
Dr. Klaus W. Wagner M.D., Ph.D.	Chief Medical Officer	633.08k	N/A	1973
Ms. Jamilu E. Rubin	Chief Financial Officer	N/A	N/A	1964
Ms. Jessica Oien J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1972
Mr. Neil Abdollahian M.B.A., M.S.	Chief Business Officer	N/A	N/A	1973
Mr. Anthony Pinkerton Ph.D.	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Ms. Meredith Wesley	Senior Vice President of Talent & Culture	N/A	N/A	N/A
Dr. Shailaja Kasibhatla Ph.D.	Senior Vice President of Discovery & Translational Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Corporate governance

Boundless Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.